News

Heart Valve Replacement for High-Risk Patients

A novel technique opens the option of transcatheter mitral valve replacement for high-risk cardiology patients.


 

Left ventricular outflow tract (LVOT) obstruction is a life-threatening complication that can put transcatheter mitral valve replacement (TMVR) out of reach for many patients. But researchers from the National Heart, Lung and Blood Institute (NHLBI) and Emory University in Atlanta, Georgia, have developed a novel technique to essentially slice through the obstacle, increasing treatment options for high-risk patients.

TMVR is a less invasive alternative to open-heart surgery. Physicians replace the mitral valve by inserting an artificial valve via a catheter. In > 50% of patients, though, the heart leaflet is pushed back, blocking blood flow. In surgery, surgeons can cut out the leaflets when they replace valves, because they are looking at the open chest and the heart and can see the problem, says study author Jaffar Khan, MD, clinician at NHLBI.

The researchers describe their new method, LAMPOON, as “a transcatheter mimic of surgical chord-sparing leaflet resection.” LAMPOON involves intentional laceration of the anterior mitral valve leaflet. The operator inserts 2 catheters through the patient’s groin, up to the heart. A thread-sized electrified wire woven through the catheter splits open the leaflet.

In the LAMPOON study, the researchers evaluated the procedure’s results in 30 patients at high risk for surgical valve replacement and prohibitive risk of LVOT obstruction during TMVR.

Survival was 100%, and 30-day survival was 93% (compared with 38% reported with other methods). In all, 73% of patients met the primary outcome: a successful LAMPOON procedure followed by a successful TMVR without reintervention. No one had a stroke.

Every year > 20,000 people in the US die of heart valve disease. The researchers hope their innovative technique will help reduce that number.

Recommended Reading

New risk score predicts cardiac-device infection
Federal Practitioner
No raised risk of cardiovascular events for COPD patients on aclidinium
Federal Practitioner
Hanging by a Thread
Federal Practitioner
AFib on the rise in end-stage COPD patients hospitalized for exacerbations
Federal Practitioner
Diabetes, hypertension remission more prevalent in adolescents than adults after gastric bypass
Federal Practitioner
Don’t Worry, It’s Just a Valve Problem
Federal Practitioner
DOACs surpass warfarin in low-weight AFib patients
Federal Practitioner
Lipoprotein(a) levels can guide CV risk assessment and treatment
Federal Practitioner
Having unmet social needs ups cardiovascular risk
Federal Practitioner
Teva expands its recall of losartan lots
Federal Practitioner